Miglustat hydrochloride NEW
| Price | $34 | $48 | $80 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Miglustat hydrochloride | CAS No.: 210110-90-0 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Miglustat hydrochloride |
| Description | Miglustat hydrochloride (N-Butyldeoxynojirimycin hydrochloride) is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease. |
| In vivo | Consumption of a standard high-fat breakfast within 30 minutes before administration of Miglustat hydrochloride significantly reduced peak exposure but did not significantly affect the extent of systemic exposure to Miglustat hydrochloride. The Cmax decreased by 36% on average following administration with food. AUC showed a modest (14%) decrease with food, but the 90% confidence interval was within the acceptance limit of 80% to 125%. Tmax was prolonged from 2.5 (1.0-4.0) hours in the fasted state to 4.5 (1.5-8.0) hours in the fed state, whereas the apparent terminal half-life was approximately 8 hours and not affected by food[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 34 mg/mL (132.95 mM) DMSO : 60 mg/mL (234.61 mM), Sonication is recommended. |
| Keywords | N-Butyldeoxynojirimycin Hydrochloride | N-Butyldeoxynojirimycin | OGT-918 | type I gaucher disease | Miglustat | Miglustat hydrochloride | oral | Glucosylceramide Synthase (GCS) | OGT918 | Miglustat Hydrochloride | OGT918 Hydrochloride | ceramide glucosyltransferase | NB-DNJ | Inhibitor | inhibit | OGT 918 | OGT 918 Hydrochloride | OGT-918 Hydrochloride | NB-DNJ Hydrochloride |
| Inhibitors Related | Serotonin hydrochloride | Risedronic Acid | Entacapone | Alendronate sodium hydrate | Flopropione |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $38.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1kg |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2022-10-28 | |
| $30.00/1KG |
Wuhan Ruichi Technology Co., Ltd
|
2024-01-03 | ||
| $10.00/1kg |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-25 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY